60 related articles for article (PubMed ID: 24531173)
1. For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features.
Fogli M; Iaria M; Focá E; Giagulli C; Caccuri F; Maggi F; Torti C; Caruso A; Fiorentini S
New Microbiol; 2014 Jan; 37(1):75-80. PubMed ID: 24531173
[TBL] [Abstract][Full Text] [Related]
2. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
Chitra P; Bakthavatsalam B; Palvannan T
Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
4. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
5. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M
HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
[TBL] [Abstract][Full Text] [Related]
6. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T-lymphocyte count/CD8+ T-lymphocyte count ratio: surrogate for HIV infection in infants?
Navaneethapandian PG; Karunaianantham R; Subramanyan S; Chinnayan P; Chandrasekaran P; Swaminathan S
J Trop Pediatr; 2012 Oct; 58(5):394-7. PubMed ID: 22228820
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
9. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
10. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
Beran O; Holub M; Spála J; Kalanin J; Stanková M
Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
[TBL] [Abstract][Full Text] [Related]
11. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
12. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
13. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.
Tuaillon E; Al Tabaa Y; Baillat V; Segondy M; Picot MC; Reynes J; Vendrell JP
Cytometry B Clin Cytom; 2009 Jul; 76(4):249-60. PubMed ID: 19072838
[TBL] [Abstract][Full Text] [Related]
14. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
[TBL] [Abstract][Full Text] [Related]
16. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
[TBL] [Abstract][Full Text] [Related]
17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
18. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution.
Murdaca G; Contini P; Setti M; Cagnati P; Lantieri F; Indiveri F; Puppo F
Clin Immunol; 2009 Nov; 133(2):238-44. PubMed ID: 19762282
[TBL] [Abstract][Full Text] [Related]
19. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
[TBL] [Abstract][Full Text] [Related]
20. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.
Li T; Wu N; Dai Y; Qiu Z; Han Y; Xie J; Zhu T; Li Y
Clin Infect Dis; 2011 Nov; 53(9):944-51. PubMed ID: 21960716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
